Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by Trevi Therapeutics, Inc. on June 13, 2024. The Company is a Delaware corporation with its principal executive offices in New Haven, Connecticut, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "TRVI".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals at the Annual Meeting:
- Election of Directors: Three nominees were elected as Class II directors for terms expiring at the 2027 annual meeting.
- Dominick Colangelo: 47,134,746 votes For; 104,348 votes Withheld; 6,825,772 Broker Non-Votes.
- Edward Mathers: 32,688,731 votes For; 14,202,702 votes Withheld; 7,173,433 Broker Non-Votes.
- David Meeker, M.D.: 33,561,857 votes For; 13,329,576 votes Withheld; 7,173,433 Broker Non-Votes.
- Ratification of Auditors: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified.
- For: 54,024,710
- Against: 26,391
- Abstain: 13,765
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Confirm the specific terms of the engagement with Ernst & Young LLP for the 2024 fiscal year.
- Review the Company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.